The Small Animal Cancer Imaging Research Facility (SACIRF) provides cancer investigators with the latest technology and techniques for experimental in vivo imaging of small animals. The facility includes state-ofthe- art instrumentation, including the modalities of magnetic resonance (MR, Bruker4.7 T, 40 cm Biospec), x-ray computed tomography (micro-CT from Enhanced Vision Systems and volume CT being developed in collaboration with General Electric), projection radiography (Faxitron), and nuclear imaging (M.Cam gamma camera from Siemens and micro-PET from Concorde Microsystems). Optical imaging will be added during the first year of the award (instrumentation to be developed in collaboration with Biomedical Engineering at The University of Texas-Austin). This instrumentation represents a >$3M investment by MDACC. The SACIRF has allocated space for the instruments in the animal support facilities to facilitate the inclusion of the imaging studies in ongoing cancer research, and dedicated office and developmental laboratory space to support the facility operation. The faculty and staff are well-qualified in each of the modality areas, including current image acquisition and image analysis techniques. Specialty areas include quantitative tissue characterization (MR), imaging of microvascular physiology (MR, nuclear, CT and optical), diffusion imaging for estimating cellular density (MR), metabolic imaging (nuclear, positron emission tomography [PET], optical and MR spectroscopy), and vascular imaging (MR, CT, and x-ray). The services of the facility include imaging protocol design, custom positioning systems, custom data acquisition hardware and software, image analysis, data archiving, provision of hardcopy and digital data delivery, and database maintenance. The Veterinary Core includes a dedicated support team that provides highly efficient imaging studies and a very low mortality rate of animals during the imaging procedures. Services provided from the Veterinary Core include development of veterinary support protocols specific to each experimental design, and consultation on the inclusion of imaging procedures into existing protocols to obtain Institutional Animal Care and Use Committee approval. To date, 75 investigators representing 13 programs have used facility instrumentation. 42% of the users are peer-review-funded investigators. Utilization continues to increase as the facility and its capabilities become better known to the local cancer research community. The capabilities of the facility continue to grow to meet experimental demands. Publications are evolving at a rapid pace, and although only a few are published, the acceptance rate has been nearly 100%. Funding for the SACIRF is currently CCSG (43%), user fees (36%), and MDACC (21%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$236,872
Indirect Cost
$83,063
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Scruggs, Stacie; Mama, Scherezade K; Carmack, Cindy L et al. (2018) Randomized Trial of a Lifestyle Physical Activity Intervention for Breast Cancer Survivors: Effects on Transtheoretical Model Variables. Health Promot Pract 19:134-144
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Roman-Gonzalez, Alejandro; Zhou, Shouhao; Ayala-Ramirez, Montserrat et al. (2018) Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268:172-178
Wang, Yugang; Guo, Yusong R; Xing, Dongming et al. (2018) Supramolecular assembly of KAT2A with succinyl-CoA for histone succinylation. Cell Discov 4:47
Okuno, Masayuki; Gourmard, Claire; Mizuno, Takashi et al. (2018) Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival. HPB (Oxford) 20:57-63
Naqvi, Kiran; Cortes, Jorge E; Luthra, Raja et al. (2018) Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107:689-695
Bose, Prithviraj; Nazha, Aziz; Komrokji, Rami S et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132:2100-2103
Loehrer, Andrew P; Chang, David C; Song, Zirui et al. (2018) Health Reform and Utilization of High-Volume Hospitals for Complex Cancer Operations. J Oncol Pract 14:e42-e50

Showing the most recent 10 out of 12418 publications